KPTI

8.97

9.93% 0.81

Handel nachbörslich: 9.27 0.30 +3.34%

Karyopharm Therapeutics Inc (KPTI)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$8.16

Offen:

$8.3

24-Stunden-Volumen:

503.24K

Relative Volume:

0.56

Marktkapitalisierung:

$203.29M

Einnahmen:

$146.07M

Nettoeinkommen (Verlust:

$-196.04M

KGV:

-0.5397

EPS:

-16.621

Netto-Cashflow:

$-75.37M

1W Leistung:

+20.08%

1M Leistung:

+3.58%

6M Leistung:

+61.62%

1J Leistung:

+95.42%

1-Tages-Spanne:

$8.22

$9.055

1-Wochen-Bereich:

$7.38

$9.055

52-Wochen-Spanne:

$3.6503

$10.99

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Firmenname

Karyopharm Therapeutics Inc

Sektor

Healthcare (1111)

Branche

Biotechnology (621)

Telefon

617-658-0600

Adresse

85 WELLS AVENUE, NEWTON, MA

Mitarbeiter

228

Twitter

@Karyopharm

Nächster Verdiensttermin

2026-05-14

Neueste SEC-Einreichungen

KPTI's Discussions on Twitter

Compare KPTI vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
KPTI Karyopharm Therapeutics Inc	8.97	184.93M	146.07M	-196.04M	-75.37M	-16.62
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-10	Eingeleitet	Rodman & Renshaw	Buy
2026-02-05	Eingeleitet	Cantor Fitzgerald	Overweight
2025-10-13	Hochstufung	H.C. Wainwright	Neutral → Buy
2025-07-16	Herabstufung	H.C. Wainwright	Buy → Neutral
2025-07-11	Fortgesetzt	H.C. Wainwright	Buy
2023-01-19	Eingeleitet	Piper Sandler	Overweight
2022-11-04	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2022-02-09	Hochstufung	JP Morgan	Underweight → Neutral
2021-11-19	Fortgesetzt	Morgan Stanley	Equal-Weight
2021-08-06	Herabstufung	JP Morgan	Overweight → Neutral
2021-08-06	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2021-08-06	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2020-07-02	Eingeleitet	Morgan Stanley	Overweight
2020-03-04	Eingeleitet	Barclays	Overweight
2020-01-17	Herabstufung	Wedbush	Outperform → Neutral
2019-07-23	Hochstufung	JP Morgan	Neutral → Overweight
2019-07-05	Bestätigt	H.C. Wainwright	Buy
2019-07-05	Bestätigt	Robert W. Baird	Outperform
2019-03-01	Herabstufung	JP Morgan	Overweight → Neutral
2019-02-28	Bestätigt	BofA/Merrill	Underperform
2019-02-27	Herabstufung	BofA/Merrill	Neutral → Underperform
2019-01-03	Hochstufung	BofA/Merrill	Underperform → Neutral
2018-12-03	Eingeleitet	B. Riley FBR	Buy
2018-11-09	Hochstufung	Wedbush	Neutral → Outperform
2018-05-24	Herabstufung	Wedbush	Outperform → Neutral
2018-04-02	Fortgesetzt	Leerink Partners	Outperform
2017-11-15	Fortgesetzt	H.C. Wainwright	Buy
2017-09-15	Eingeleitet	RBC Capital Mkts	Outperform
2016-09-08	Bestätigt	H.C. Wainwright	Buy
2016-08-30	Hochstufung	Jefferies	Hold → Buy
2016-08-18	Eingeleitet	H.C. Wainwright	Buy
2016-06-28	Eingeleitet	Robert W. Baird	Outperform

Alle ansehen

Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten

04:17 AM

Karyopharm (KPTI) director Christy Oliger receives 15,508 RSU equity award - Stock Titan

04:17 AM

04:15 AM

Karyopharm (KPTI) director awarded 15,508 RSUs vesting in 2027 - Stock Titan

04:15 AM

04:13 AM

Karyopharm Therapeutics (KPTI) director receives 15,508 RSUs in equity award - Stock Titan

04:13 AM

04:12 AM

Karyopharm (KPTI) director receives 15,508 RSU equity award vesting in 2027 - Stock Titan

04:12 AM

04:06 AM

Karyopharm (NASDAQ: KPTI) director gets 15,508 RSUs vesting in 2027 - Stock Titan

04:06 AM

08:04 AM

Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts - Yahoo Finance

08:04 AM

07:06 AM

Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus - Yahoo Finance

07:06 AM

May 24, 2026

KPTI PE Ratio & Valuation, Is KPTI Overvalued - Intellectia AI

May 24, 2026

May 22, 2026

KPTI Stock Price, Quote & Chart | KARYOPHARM THERAPEUTICS INC (NASDAQ:KPTI) - ChartMill

May 22, 2026

May 20, 2026

Karyopharm rises on securing $100M in financing to extend cash runway into Q2 2026 - MSN

May 20, 2026

KPTI Technical Analysis | Trend, Signals & Chart Patterns | KARYOPHARM THERAPEUTICS INC (NASDAQ:KPTI) - ChartMill

May 20, 2026

Karyopharm (KPTI) Leans on SENTRY in Pivotal Call - TipRanks

May 20, 2026

Earnings call transcript: Karyopharm Q1 2026 results disappoint, stock drops By Investing.com - Investing.com Australia

May 20, 2026

Earnings call transcript: Karyopharm Q1 2026 results disappoint, stock drops - Investing.com UK

May 20, 2026

May 17, 2026

RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI) - The Globe and Mail

May 16, 2026

May 15, 2026

Opaleye Management Inc. Reduces Stake in Karyopharm Therapeutics Inc. - GuruFocus

May 15, 2026

Ikarian Capital (KPTI) files joint 13G showing sub‑5% holding - Stock Titan

May 15, 2026

Karyopharm Therapeutics CAO Kristin Abate sells $503 in stock By Investing.com - Investing.com South Africa

May 15, 2026

Karyopharm Therapeutics CAO Kristin Abate sells $503 in stock - Investing.com

May 15, 2026

Karyopharm (KPTI) EVP nets PSUs, then small tax-driven share sale - Stock Titan

May 15, 2026

[Form 4] Karyopharm Therapeutics Inc. Insider Trading Activity - Stock Titan

May 15, 2026

Karyopharm (KPTI) EVP earns PSU shares, sells 324 to cover taxes - Stock Titan

May 15, 2026

Karyopharm (KPTI) CAO reports PSU vesting and small pre-planned tax sale - Stock Titan

May 15, 2026

Karyopharm (KPTI) CEO logs PSU vesting and automatic tax-related share sale - Stock Titan

May 15, 2026

Karyopharm (KPTI) EVP sale covers tax on earned PSU award - Stock Titan

May 15, 2026

Karyopharm (KPTI) Schedule 13G: Acorn entities and Anders Hove report 1.52M shares - Stock Titan

May 15, 2026

RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $16 - Moomoo

May 15, 2026

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2026 Earnings Call Transcript - Insider Monkey

May 15, 2026

[EFFECT] Karyopharm Therapeutics Inc. SEC Filing - Stock Titan

May 15, 2026

Karyopharm Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm

May 15, 2026

May 14, 2026

Karyopharm Therapeutics 1Q Loss/Shr $1.24 >KPTI - Moomoo

May 14, 2026